Search

Displaying results 331 - 340 of 7452 in total
  1. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    that are important for protein metabolism in the epithelium [A32373]. … Panthenol exists as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol).

    Mixtures: All New TS, ReEn Mogangbichaek for Sensitive ScalpProducts: Roota Re F for men, Roota Re V for women
  2. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA...

    Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLProducts: LYXUMIA (SOLUTION FOR INJECTION 10 MCG), LYXUMIA (SOLUTION FOR INJECTION 20 MCG)
  3. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA appro...

    Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MG
  4. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

    Products: INVEGA Sustenna Prolonged Release Suspension for IM Injection 25mg/0.25 ml, INVEGA Sustenna Prolonged Release Suspension for IM Injection 50mg/0.5 ml
  5. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    [L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.

    Categories: Agents for Dermatitis, Excluding CorticosteroidsProducts: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled Syringe
  6. Drug

    Streptomycin

    go.drugbank.com/drugs/DB01082
    ApprovedInvestigationalVet approved

    [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Streptomycin for Injection USP, STREPTOMYCIN SULFATE FOR INJECTION 1 g/vial
  7. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...

    Products: FORTEO 250 UG SOLUTION FOR INJECTION, KAULIV 20 micrograms/80 microliters solution for injection
  8. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.

    Products: KEYTRUDA SOLUTION FOR INFUSION 25MG/ML, Keytruda 100mg Solution for Infusion
  9. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.

    Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
  10. Drug

    Somatotropin

    go.drugbank.com/drugs/DB00052
    ApprovedInvestigational

    [A228188] Recombinant growth hormone is available as a subcutaneous injection for children and adults under a wide variety of brand names. … [A228183] Growth hormone therapy is approved for various disorders of growth hormone deficiency, growth failure, or short stature including Turner syndrome, chronic renal insufficiency before transplantation

    Products: ZOMACTON Powder and Solvent for Solution for Injection 10mg, ZOMACTON Powder and Solvent for Solution for Injection 4 mg